Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Archives de pédiatrie
Volume 20, n° 5S1
pages H146-H147 (mai 2013)
Doi : 10.1016/S0929-693X(13)71364-2
TR31 – Quelle fertilité après un traitement par chimiothérapie ?

Autogreffe ovarienne : quel risque de réintroduire la pathologie après une leucémie ou un cancer traité dans l’enfance ?
 

F. Chambon a, b, c, , A. Tchirkov c, d, F. Brugnon c, e, J. Kanold a, b, c
a CHU Clermont-Ferrand, Centre Régional de cancérologie et thérapie cellulaire pédiatrique, Hôpital Estaing, Clermont-Ferrand, France 
b INSERM-CIC 501, F-63003 Clermont-Ferrand, France 
c Clermont Université, Université Clermont1, Faculté de Médecine, Clermont-Ferrand, France 
d CHU de Clermont-Ferrand, Service de cytogénétique médicale, Hôpital Estaing, Clermont-Ferrand, France 
e Assistance médicale à la procréation, CECOS, CHU Estaing, Clermont-Ferrand, France 

*Auteur correspondant.


© 2013  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline